Abstract:A total of 31 patients with 45 episodes of failing arteriovenous dialysis fistulas was studied. Fistula failure was usually due to venous and/or anastomotic stenosis, often in conjunction with thrombosis. Abnormalities were treated by percutaneous dilation and occasionally streptokinase infusion. Most complications and failures occurred either in patients with recently created fistulas or in those with multiple or long segment stenosis associated with thrombosis. Patients with a single nonobstructing stenosis … Show more
“…Carbon dioxide was used as a contrast agent in all cases to identify anterior calices before the definitive puncture for nephrostomy drainage, and an anterior caliceal approach was used in all cases [4]. Initial nephrostomy catheter placement was either confined to the renal pelvis or done with internal-external ureteral stenting to the bladder.…”
“…Carbon dioxide was used as a contrast agent in all cases to identify anterior calices before the definitive puncture for nephrostomy drainage, and an anterior caliceal approach was used in all cases [4]. Initial nephrostomy catheter placement was either confined to the renal pelvis or done with internal-external ureteral stenting to the bladder.…”
“…The clinical presentation of dialysis access failure is varied [8,9], Thrombosis is the most common presenta tion and is frequently the result of venous limb stenosis and resultant decreased blood flow. High venous resis tance measured during dialysis may be the first clue to impending access failure.…”
Vascular access failure in hemodialysis patients remains a significant problem. The use of thrombolytic agents and balloon angioplasty instead of or in conjunction with surgical revision, has been helpful in increasing the life span of vascular access in these patients. The application of newer endovascular therapies, such as vascular stents, may further improve the salvage rate of hemodialysis access sites. These stents may be particularly valuable in treating stenoses in large central veins. We present 2 cases in which a balloon-expandable Palmaz® stent was used to treat a central venous stenosis causing signs of vascular access failure.
“…The most favored one is the subcutaneous radial artery-to-cephalic vein fistula in the distal forearm. Patency rates for those accesses are quite good and amount to 70-90% at 3 years [1][2][3]. However, thrombosis of the vascu lar access, which is the most frequent complication, may result in a complete loss of the fistula.…”
In 17 out of 29 hospitalized patients (58.6%) with internal arteriovenous fistula (AVF) thrombosis a systemic streptokinase infusion was used as an alternative to urgent surgical declotting. In the remaining 12 patients (41.4%) fibrinolytic treatment was contraindicated due to the necessity for immediate dialysis, uncontrolled hypertension, active peptic ulcer, known multilevel stenoses of the fistula, or operation 8 days prior to the thrombosis. The systemic streptokinase therapy alone was successful in 9 of 17 patients treated (52.9%), 5 of 17 patients (29.4%) needed the combined therapy (streptokinase plus surgery) and in 3 of 17 patients (17.6%) the fibrinolytic therapy was unsuccessful. No serious complications attributable to the streptokinase infusion were observed. Systemic streptokinase treatment for acute AVF declotting followed by the radiological evaluation of the vessels can be a reasonable alternative to ‘blind’ surgical emergency reconstruction. The method makes it possible to identify those underlying anatomic abnormalities of the draining vein which may be localized at some distance from the anastomosis and so overlooked during surgery.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.